Buy Like Buffett
Watchlist

Flagship explainer

How Bionano Genomics, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$28.5M · 100%Cost of revenue$15.3M · 54%Gross profit$13.2M · 46%Operating income−$33.3M · −117%Income before tax−$26.3M · −92%Income tax$67000 · 0%Net income−$26.4M · −93%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$28.5M100%
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
Cost of revenue$15.3M54%
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
$13.2M46%
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
−$33.3M−117%
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
Income before tax−$26.3M−92%
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
Income tax$670000%
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
−$26.4M−93%
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001411690-26-000007 · filed Mar 23, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full Bionano Genomics, Inc. analysis at Buy Like Buffett